Does smoking affect level of seropositivity in RA? A post-HOC global and inter-country analysis of COMORA cohort
- 24 February 2021
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 41 (4) , 699-705
Abstract
To study the association of smoking status and the level of seropositivity in RA patients from COMORA Cohort. A post hoc analysis of COMORA database included 3439 RA patients was performed. Current smokers or recently quitted (< 3 years) were initially compared to those who never smoked or stopped > 3 years (Group I vs. II) regarding their seropositivity status (high positive, low positive and negative) for Rheumatoid Factor (RF) or Anti-citrullinated antibodies (ACPA). A further comparison was made between current smokers (Group III) and never smoked patients (Group IV). Analysis was also done on the individual country level for the 17 countries included in the COMORA study. Out of 3439 RA patients, 705 (20.5%) were smokers (group I), and 2734 (79.5%) were non-smokers (group II). Significantly more patients in group I, 442 (62.7%), had high levels of seropositivity than those in group II, 1556 (56.9%), [P = 0.006, OR 1.27 (95% CI, 1.07–1.5)]. More current smoker patients (group III—286 out of 456 “62.7%”) had high levels of seropositivity than never smoked patients (group IV—1236 out of 2191 “56.4%”), with significant difference [P = 0.013, OR 1.3 (95% CI, 1.06–1.6)]. In 11 countries, higher proportions of patients with high level of seropositivity in group I was found, with statistical significance in four countries. Smoking was associated with higher level of seropositivity in patients with RA in this post hoc analysis, both on a global level and in certain individual countries. As smoking is a modifiable risk factor, studying the effects of quitting smoking on level of seropositivity and other disease parameters is warranted.Keywords
This publication has 32 references indexed in Scilit:
- Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profileAnnals of the Rheumatic Diseases, 2013
- Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritisArthritis Research & Therapy, 2012
- Modifiable risk factors for RA: prevention, better than cure?Rheumatology, 2011
- Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smokeAnnals of the Rheumatic Diseases, 2011
- The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritisArthritis Research & Therapy, 2010
- Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studiesAnnals of the Rheumatic Diseases, 2010
- Rheumatoid arthritis and smoking: putting the pieces togetherArthritis Research & Therapy, 2009
- Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cellsAnnals of the Rheumatic Diseases, 2008
- Interaction between smoking, the shared epitope, and anti–cyclic citrullinated peptide: A mixed picture in three large North American rheumatoid arthritis cohortsArthritis & Rheumatism, 2007
- Strong combined gene–environment effects in anti–cyclic citrullinated peptide–positive rheumatoid arthritis: A nationwide case–control study in DenmarkArthritis & Rheumatism, 2007